

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **August 12, 2025**

**NEXGEL, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**001-41173**

(Commission  
File Number)

**26-4042544**

(IRS Employer  
Identification No.)

**2150 Cabot Boulevard West, Suite B  
Langhorne, Pennsylvania**

(Address of principal executive offices)

**19047**

(Zip Code)

Registrant's telephone number, including area code: **(215) 702-8550**

(Former name or former address, if changed since last report)

**Not Applicable**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, par value \$0.001	NXGL	The Nasdaq Capital Market LLC
Warrants to Purchase Common Stock	NXGLW	The Nasdaq Capital Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02 Results of Operations and Financial Condition**

On August 12, 2025, NexGel, Inc. (the “*Company*”) issued a press release reporting the Company’s results for the quarter ended June 30, 2025, a copy of which is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

**Item 7.01 Regulation FD Disclosure.**

On August 12, 2025, the Company began utilizing a new investor presentation, a copy of which is attached hereto as Exhibit 99.2.

The information in Items 2.02 and 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “*Exchange Act*”), nor shall Exhibits 99.1 and 99.2 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit No.	Description
99.1	<a href="#">Press release of NexGel, Inc. issued August 12, 2025.</a>
99.2	<a href="#">NexGel, Inc. Investor Presentation, dated August 2025.</a>
104	Cover Page Interactive Data File (formatted as Inline XBRL)

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 12, 2025

**NEXGEL, INC.**

By: /s/ Adam Levy  
Adam Levy  
Chief Executive Officer

---



## NEXGEL Reports Second Quarter 2025 Financial Results

*Second quarter 2025 revenue totaled \$2.88 million, an increase of 100.3% as compared to \$1.44 million for the same period year-over-year*

*Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024*

*Company is reiterating revenue guidance for 2025 of \$13 million and to achieve positive EBITDA during the year*

**LANGHORNE, Pa. – August 12, 2025** – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its second quarter 2025 financial results for the period ending June 30, 2025.

### Second Quarter 2025 Financial Highlights:

- Net Revenue was \$2.88 million, compared to \$1.44 million in Q2 2024 and \$2.81 million in Q1 2025.
- Gross Profit was \$1.26 million, compared to \$0.29 million in Q2 2024 and \$1.19 million in Q1 2025.
- Gross Profit Margin was 43.6%, compared to 20.3% in Q2 2024 and 42.4% in Q1 2025.
- Net loss attributable to NEXGEL stockholders was \$0.67 million, compared to \$0.89 million in Q2 2024 and \$0.71 million in Q1 2025.
- EBITDA<sup>1</sup>, a non-GAAP financial measure, was (\$0.53) million, compared to EBITDA of (\$0.58) million in Q1 2025 and an EBITDA of (\$0.73) million in Q4 2024.
- Adjusted EBITDA<sup>1</sup>, a non-GAAP financial measure, was (\$0.42) million, compared to Adjusted EBITDA of (\$0.50) million in Q1 2025 and Adjusted EBITDA of (\$0.62) million in Q4 2024.

“For the second quarter of 2025 we reported strong revenue and gross margin with a steady decline of our Adjusted EBITDA loss as we head into seasonally a strong second half of the year. The year-over-year growth was led by growth in consumer demand for our branded products and new agreements in contract manufacturing. In both parts of our business, we expect significant growth opportunities in the second half of 2025 as new consumer product launches for our brands come online and we onboard new contract manufacturing customers in our robust pipeline,” said Adam Levy, Chief Executive Officer of NEXGEL. “Subsequent to the quarter, we expanded our partnership with STADA, which includes a \$1 million advance in non-dilutive capital to support product launches and marketing efforts. Additionally we closed on financings for \$1.05 million in gross proceeds, which is sufficient to support our upcoming growth initiatives. We remain confident in our previously issued guidance for 2025 of \$13 million in revenue and to achieve positive EBITDA during the year.”

### Second Quarter 2025 Financial Results

For the second quarter of 2025, revenue totaled \$2.88 million, an increase of 100.3%, as compared to \$1.44 million for the second quarter of 2024. The increase in overall revenues was primarily due to sales growth in both contract manufacturing and branded products.

Cost of revenues totaled \$1.63 million for the second quarter of 2025, as compared to \$1.15 million for the second quarter of 2024. The increase in cost of revenues is primarily aligned with sales of branded consumer products, as Silly George was acquired midway through the comparable 2024 time period.

Gross profit totaled \$1.26 million for the second quarter of 2025, as compared to a gross profit of \$0.29 million for the second quarter of 2024. Gross profit margin for the second quarter of 2025 was 43.6%, as compared to 20.3% for the second quarter of 2024. The increase of \$0.97 million in gross profit on a year-over-year basis was primarily due to both an increase in contract manufacturing and consumer branded products given the acquisition of Silly George midway through the comparable 2024 time period.

Selling, general and administrative expenses totaled \$1.89 million for the second quarter of 2025, as compared to \$1.27 million for the second quarter of 2024. The increase year-over-year was attributable to increases in compensation and benefits, share-based compensation, advertising, professional and consulting fees, other fees, and investor and shareholder services, which was partly offset by a decrease in depreciation and amortization.

EBITDA<sup>1</sup>, a non-GAAP financial measure, totaled (\$0.53) million for the second quarter of 2025 as compared to (\$0.76) million for the second quarter of 2024.

Adjusted EBITDA<sup>1</sup>, a non-GAAP financial measure, totaled (\$0.42) million for the second quarter of 2025 as compared to (\$0.79) million for the second quarter 2024.

Net loss attributable to NEXGEL stockholders for the second quarter of 2025 was \$0.67 million, as compared to a net loss of \$0.89 million for the second quarter of 2024.

As of June 30, 2025, the Company had a cash balance of approximately \$0.73 million. Subsequent to the quarter, the Company expanded its partnership with STADA, which includes a \$1 million advance in non-dilutive capital from STADA to support product launches and marketing efforts. Additionally, the Company closed on financings for \$1.05 million in gross proceeds.

As of August 12, 2025, NEXGEL had 8,067,580 shares of common stock outstanding.

1. EBITDA and Adjusted EBITDA are a non-GAAP measures described in the section titled "Non-GAAP Financial Measures" below and reconciled to the most directly comparable GAAP measures at the end of this release.

## **Second Quarter 2025 Financial Results Conference Call**

**Date:** August 12, 2025

**Time:** 4:30 p.m. ET

**Live Call:** 1-800-274-8461 (U.S. Toll Free) or 1-203-518-9814 (International)

**Webcast:** [Events and Presentations](#)

For interested individuals unable to join the conference call, a replay will be available through August 26, 2025, by dialing + 1-844-512-2921 (U.S. Toll Free) or + 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11159686. An archived version of the webcast will also be available for 90 days.

## **About NEXGEL, INC.**

NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal<sup>®</sup>, Hexagels<sup>®</sup>, Turfguard<sup>®</sup>, Kenkoderm<sup>®</sup> and Silly George<sup>®</sup>. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

## **Non-GAAP Financial Measures**

Certain Non-GAAP financial measures are included in this press release. In the calculation of these measures, the Company excludes certain items, such as amortization of intangible assets, stock-based compensation, tax impact of adjustments, other unusual items and discrete items impacting income tax expense. The Company believes that excluding such items provides investors and management with a representation of the Company's core operating performance and with information useful in assessing its prospects for the future and underlying trends in the Company's operating expenditures and continuing operations. Management uses such Non-GAAP measures to evaluate financial results and manage operations. The release and the attachments to this release provide a reconciliation of each of the Non-GAAP measures referred to in this release to the most directly comparable GAAP measure. The Non-GAAP financial measures are not meant to be considered a substitute for the corresponding GAAP financial statements and investors should evaluate them carefully. These Non-GAAP financial measures may differ materially from the Non-GAAP financial measures used by other companies.

## **Forward-Looking Statement**

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs, such as "will," "should," "would," "may," and "could," are generally forward-looking in nature and not historical facts, including, without limitation, our expectation for significant growth opportunities in the second half of 2025 as new consumer product launches for our brands come online and we onboard new contract manufacturing customers in our robust pipeline and our continued expectation to generate at least \$13 million in revenue for 2025 and achieve positive EBITDA during the year. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under "Risk Factors" therein, which the Company filed with the SEC and which may be viewed at <http://www.sec.gov/>.

## **Investor Contacts:**

Valter Pinto, Managing Director  
KCSA Strategic Communications  
212.896.1254  
[Nexgel@kcsa.com](mailto:Nexgel@kcsa.com)

---

**NEXGEL, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
**AS OF JUNE 30, 2025 AND DECEMBER 31, 2024**  
**(Unaudited)**  
*(in thousands, except share and per share data)*

	June 30, 2025	December 31, 2024
<b>ASSETS:</b>		
Current Assets:		
Cash	\$ 725	\$ 1,807
Accounts receivable, net	753	933
Inventory, net	1,821	1,751
Prepaid expenses and other current assets	863	623
Total current assets	4,162	5,114
Goodwill	1,128	1,128
Intangibles, net	744	807
Property and equipment, net	2,070	2,211
Operating lease - right of use asset	1,512	1,628
Other assets	95	95
Total assets	\$ 9,711	\$ 10,983
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current Liabilities:		
Accounts payable	\$ 826	\$ 761
Accounts payable - related party	447	531
Accrued expenses and other current liabilities	534	310
Deferred revenue	180	179
Current portion of note payable	99	97
Warrant liability	14	118
Contingent consideration liability	-	178
Financing lease liability, current portion	62	59
Operating lease liabilities, current portion	234	237
Total current liabilities	2,396	2,470
Operating lease liabilities, net of current portion	1,446	1,538
Financing lease liability, net of current portion	275	307
Notes payable, net of current portion	539	588
Total liabilities	4,656	4,903
Commitments and Contingencies (Note 17)	-	-
Preferred stock, par value \$0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding	-	-
Common stock, par value \$0.001 per share, 25,000,000 shares authorized; 7,654,537 and 7,638,497 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively	8	8
Additional paid-in capital	24,036	23,743
Accumulated deficit	(19,373)	(17,996)
Total NexGel stockholders' equity	4,671	5,755
Non-controlling interest in joint venture	384	325
Total stockholders' equity	5,055	6,080
Total liabilities and stockholders' equity	\$ 9,711	\$ 10,983

**NEXGEL, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
**FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND 2024**  
**(Unaudited)**  
*(in thousands, except share and per share data)*

	Three Months Ended June 30,		Six Months Ended June 30,	
	2025	2024	2025	2024
Revenues, net	\$ 2,884	\$ 1,440	\$ 5,690	\$ 2,706
Cost of revenues	1,626	1,147	3,244	2,187
Gross profit	1,258	293	2,446	519
Operating expenses:				
Research and development	-	76	1	78
Selling, general and administrative	1,894	1,271	3,858	2,366
Total operating expenses	1,894	1,347	3,859	2,444
Loss from operations	(636)	(1,054)	(1,413)	(1,925)
Other income (expense):				
Interest expense, net	(21)	(29)	(42)	(44)
Loss on sale of assets	-	(4)	-	(4)
Other expense	(37)	-	(76)	-
Other income	41	6	109	6
Gain on investments	-	23	-	57
Changes in fair value of warrant liability	13	79	104	26
Total other income (expense), net	(4)	75	95	41
Loss before income taxes	(640)	(979)	(1,318)	(1,884)
Income tax expense	-	-	-	-
Net loss	(640)	(979)	(1,318)	(1,884)
Less: Income (loss) attributable to non-controlling interest in joint venture	(25)	94	(59)	146
Net loss attributable to NexGel stockholders	\$ (665)	\$ (885)	\$ (1,377)	\$ (1,738)
Net loss per common share - basic	\$ (0.09)	\$ (0.14)	\$ (0.18)	\$ (0.28)
Net loss per common share - diluted	\$ (0.09)	\$ (0.14)	\$ (0.18)	\$ (0.28)
Weighted average shares used in computing net loss per common share - basic	7,654,348	6,254,659	7,649,878	6,118,212
Weighted average shares used in computing net loss per common share – diluted	7,654,348	6,254,659	7,649,878	6,118,212

NEXGEL, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS  
FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024  
(Unaudited)  
(in thousands)

	Six Months Ended June 30,	
	2025	2024
<b>Operating Activities</b>		
Net loss	\$ (1,377)	\$ (1,738)
Adjustments to reconcile net loss to net cash used in operating activities:		
Income (loss) attributable to non-controlling interest in joint venture	59	(146)
Depreciation and amortization	225	144
Net changes in operating lease assets and liabilities	21	22
Share-based compensation and restricted stock vesting	293	118
Gain on investment in marketable securities	—	(57)
Changes in fair value of warrant liability and warrant modification expense	(104)	(26)
Changes in operating assets and liabilities:		
Accounts receivable, net	180	28
Inventory	(70)	(127)
Prepaid expenses and other assets	(240)	(68)
Accounts payable	65	117
Accounts payable – related party	(84)	(105)
Accrued expenses and other current liabilities	224	(113)
Deferred revenue	1	159
<b>Net Cash Used in Operating Activities</b>	<b>(807)</b>	<b>(1,792)</b>
<b>Investing Activities</b>		
Proceeds from sales of marketable securities	—	57
Capital expenditures	(20)	(361)
Net cash paid for asset acquisition	—	(400)
<b>Net Cash Used in Investing Activities</b>	<b>(20)</b>	<b>(704)</b>
<b>Financing Activities</b>		
Proceeds from equity offering, net of expenses	—	946
Investment by joint venture partner	—	37
Payment of contingent consideration liability	(178)	(69)
Principal payment on financing lease liability	(29)	(22)
Principal payments of notes payable	(48)	(27)
<b>Net Cash Provided by (Used in) Financing Activities</b>	<b>(255)</b>	<b>865</b>
<b>Net Decrease in Cash</b>	<b>(1,082)</b>	<b>(1,631)</b>
Cash – Beginning of period	1,807	2,700
Cash – End of period	<u>\$ 725</u>	<u>\$ 1,069</u>
<b>Supplemental Disclosure of Cash Flows Information</b>		
Cash paid during the year for:		
Interest	<u>\$ 18</u>	<u>\$ 27</u>
Taxes	<u>\$ —</u>	<u>\$ —</u>
<b>Supplemental Non-cash Investing and Financing activities</b>		
Shares issued in conjunction with asset acquisition	<u>\$ —</u>	<u>\$ 200</u>
Property and equipment financed under notes payable	<u>\$ —</u>	<u>\$ 165</u>
Property and equipment financed under financing leases	<u>\$ —</u>	<u>\$ 416</u>



**RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES**  
**(in thousands, except per share amounts)**  
**CALCULATION OF EBITDA & ADJUSTED EBITDA**

	<b>Three Months Ended March 31,</b>	<b>Three Months Ended June 30,</b>
	<b>2025</b>	<b>2025      2024</b>
Net (loss) income:	\$ (678)	\$ (640)    \$ (979)
Less: Loss (income) attributable to non-controlling interest in joint venture	(34)	(25)      94
Net loss attributable to NexGel stockholders	(712)	(665)    (885)
Adjustments:		
Depreciation and amortization	114	111      92
Interest expense, net	21	21      29
Income tax expense	-	-      -
EBITDA	(577)	(533)    (764)
Change in warrant liability <sup>(1)</sup>	(91)	(13)      (79)
Share-based compensation expense <sup>(2)</sup>	166	127      55
Adjusted EBITDA:	\$ (502)	\$ (419)    \$ (788)

	<b>Six Months Ended June 30,</b>
	<b>2025      2024</b>
Net (loss) income:	\$ (1,318)    \$ (1,884)
Less: Loss (income) attributable to non-controlling interest in joint venture	(59)      146
Net loss attributable to NexGel stockholders	(1,377)    (1,738)
Adjustments:	
Depreciation and amortization	225      144
Interest expense, net	42      44
Income tax expense	-      -
EBITDA	(1,110)    (1,550)
Change in warrant liability <sup>(1)</sup>	(104)      (26)
Share-based compensation expense <sup>(2)</sup>	293      118
Adjusted EBITDA:	\$ (921)    \$ (1,458)

(1) This adjustment gives effect to non-cash warrant liability changes incurred during the periods.

(2) The adjustments represent share-based compensation expense related to awards of stock options, restricted stock units, or common stock in exchange for services. Although we expect to continue to award stock in exchange for services, the amount of non-cash stock-based compensation is excluded as it is subject to change as a result of one-time or non-recurring projects.



# Investor Presentation

August 2025



NASDAQ: NXGL

---

## Forward-Looking Statement

This presentation contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature.

Additional written and oral forward-looking statements may be made by the Company from time to time in filings with the Securities and Exchange Commission (SEC) or otherwise.

The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms.

These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC.

Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. Except as otherwise required by law, the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

## NEXGEL – Who We Are and What We Do

After two decades of creating custom hydrogel solutions for large medical device companies, our business today includes the development of patented medical devices, custom/white label products, and OTC healthcare consumer products.

We invested in our in-house converting and packaging capabilities to better meet our customer's evolving needs.

These strategic growth opportunities reflect our dedication to pioneering advancements across various domains, delivering great value to our customers and stakeholders.

### Agreements with Multi-Billion Dollar Corporations




abbvie



Medtronic

---

## Multiple Products & Applications for Nexgel's Technology



# Competitive Advantage:

## 1 of 2 State-of-the-Art Manufacturing Facilities in NA

*Medical grade technology and facility, providing gels to multi-national device companies for over 20 years with sufficient capacity to fulfill consumer and healthcare segments*

1 of 2 manufacturing facilities in North America that can produce state-of-the-art hydrogel transdermal products  
– successfully used 200+ different active ingredient combinations to date



16,500-square-ft GMP  
13,500-square-ft  
manufacturing space

3,000-square-ft office  
space

>1.4 Billion square inches  
of product per year is  
total capacity

Sufficient capacity across  
healthcare and consumer  
divisions



Electron Beam  
Accelerator eliminates  
the need for harmful  
chemicals in hydrogel  
production

High barrier to entry  
for new facilities  
(2+ yrs to go live)

Stringent compliance  
requirements

Technical expertise  
needed to operate

NASDAQ: NXGL



---

## Converting and Packaging Facility

*50% ownership in converting and packaging business in Granbury, Texas*

- Significant synergies which enable the onboarding of potential finished goods customers along with enhanced combined marketing and outreach efforts
- Increased square footage and installed cutting-edge automated machinery in our clean room facilities to support anticipated growth
- CG Labs converting and packaging division is one of NEXGEL's largest customers



NASDAQ: NXGL



# Hydrogels for Consumer and Medical Applications

- Electron beam technology eliminates the need for harmful chemicals in cross-linking, which, along with our paraben-free formulation, makes our patches the only option for many medical device applications and preferred among consumers
- Gentle formulation & strong adhesion properties eliminates many problems with existing transdermal devices & dermal interfaces such as:
  - Deterioration of skin integrity
  - Skin allergies
  - Skin irritation
  - Discomfort
  - Skin tears
  - Removal of dermis
  - Pain

*All of these contribute to increased risk  
of infection and overall patient  
dissatisfaction*



# Current Medical Device Pipeline

Addressing the importance of skin integrity and overall skincare with a medical device



NASDAQ: NXGL



# Medical Device Pipeline: Drug Delivery

*Potential for Multiple Drug Delivery Applications through Unique Hydrogel Technology*

## Drug Delivery: *Diclofenac Patch*


To treat short-term pain due to preclinical sprains and bruises

## Drug Delivery: *Apremilast Patch*

To treat autoimmune conditions, such as arthritis and psoriasis

- Promising pre-clinical human results (12 patients)
- Proof-of-concept study completed, validating the potential value of our hydrogel technology for pain indications (arthritis, joint pain, etc.)
- Compared to the current market, NEXGEL's product demonstrated enhanced efficacy (faster-acting, longer lasting, with no mess)

Comparative In-Vitro<sup>1</sup> Human Skin Permeation of Diclofenac Sodium from NEXGEL Patch After 8 Hours



<sup>1</sup>. In-vitro skin permeation performed using full-thickness derma to med human cadaver skin; 250 microns thick in Franz cells (3.65 ml volume with 0.95 cm<sup>2</sup> surface area) at 37°C. Receptor compartment contained pH 7.4 PBS. 4 cells per formulation sample. Sampling times at 2, 4, and 8 hours. Analysis by HPLC.

<sup>2</sup>. Skin samples were removed from Franz cell after 8 hours permeation experiment and extracted in ethanol for 12 hours at 37°C. Analysis by HPLC.

# Consumer Health & Beauty

Bringing proven medical-grade technology to OTC and B&C for the first time through many new consumer products & applications



NASDAQ: NXGL

# NEXGEL Branded Products

NOW PARABEN-FREE



NASDAQ: NXGL



“

"A little hexagon miracle! I felt immediate relief. I was astounded and will be a customer for life!"

~ Medagel Customer

---

# M&A Strategy: Consumer Brand Acquisition

## Kenkoderm Skincare Line

- Acquisition completed in December 2023
- Complimentary line of alternative psoriasis treatments
- Profitable (ttm) and immediately accretive
- 6 SKUs sold primarily DTC with significant portion of revenue derived from subscription bundles



Synergies support optimization of marketing and supply chain operations to drive revenue growth and margins

New marketing strategies and distribution channels in place to reach a wider consumer base

NASDAQ: NXGL

## Silly George Beauty Brand

- Acquisition completed in May 2024
- Specialty eye and eyelash consumer product line
- Annual run-rate of \$2mm when purchased, now over \$5mm
- Currently DTC and on Amazon
- Social media following: 89,000 Facebook and 86,000 Instagram followers + 254,000 active customer emails



---

## Cintas Corporation

*Cintas is a leading provider of corporate identify uniforms, first aid and safety products and services to over 1 million businesses across North America*

- Cintas will distribute SilverSeal, NEXGEL's hospital-grade dressing for wounds and burns to its customers in many sectors including hospitality and public service.
- This wound care solution will be available for employees of their customers.
- Partnership is significant for associated revenue, but also brand recognition awareness among this consumer demographic.
- The initial order of SilverSeal was successfully delivered to Cintas in the fourth quarter of 2024 and has led to additional orders in Q1 '25.

---

## STADA Arzneimittel AG

*Partnership with a leading European consumer health company accelerates the expansion of NEXGEL's OTC product portfolio*

- STADA, a global leader in consumer healthcare, generics, and specialty pharmaceuticals with sales in ~120 countries, is using this partnership to establish a path into the North American market.
- Strategic, mutually beneficial partnership that enhances NEXGEL's product portfolio and enables distribution and commercialization of STADA's consumer health OTC products.
- Their first joint product is Histasolv (sold as Daosin in Europe), the continent's top-selling DAO enzyme supplement for histamine intolerance, generating over \$20 million in annualized European revenue.
- Histasolv launched in Q3 2024 with strong sales growth; STADA agreed to provide \$1 million in non-dilutive capital to expand the partnership and support new product launches in Q4 2025 and early 2026, including digestive enzyme products for new indications, scar treatments, and stretch mark solutions.



## AbbVie (NYSE: ABBV)

*CG Converting and Packaging is the exclusive supplier of gel pads to be used with AbbVie's Rapid Acoustic Pulse device for the improvement in the appearance of cellulite*

- Allergan Aesthetics, acquired by AbbVie, purchased Soliton, the owner of the Resonic technology, for \$550 million in December 2021
- Leveraging NEXGEL's proprietary hydrogel technology, the gel pads are an important component and must be used FOR ALL body contouring device treatments
- In Q1 '24, received a non-refundable \$176,000 deposit from Abbvie against their first order



NASDAQ: NXGL

THE WALL STREET JOURNAL.  
**Allergan Aesthetics  
Completes \$550M  
Acquisition of Soliton**

December 22, 2021





# New Partnerships & Customers

## Reducing Carcinogenic Plume in Laser Hair Removal

- *An FDA-compliant IRB study conducted by Innovative Optics evaluating NEXGEL hydrogel's efficacy in reducing harmful plume during laser hair removal.*
- *30-patient trial at Florida Clinical Research Center.*
- *Data publication shortly with commercial launch in 2025 upon meeting endpoint of study.*
- *Well over a dozen states have enacted legislation mandating the use of plume evacuation systems in order to mitigate hazards and risks of exposure to plume.*

## iRhythm's (NASDAQ: IRTC) ECG Heart Monitor

- *Supply iRhythm with our ultra-gentle, high-moisture hydrogel for integration into the Zio® ECG heart monitor.*
- *Zio is a single-use ECG heart monitor that provides a continuous, single-channel recording for up to 14 days.*
- *Monitor is worn on the upper left chest, & uses NEXGEL's hydrogel wings for secure, comfortable wear and easy removal.*
- *iRhythm's Zio heart monitor showcases another impactful application for our skin-friendly, dermatologically safe technology.*




NASDAQ: NXGL

iRHYTHM



## Revenue for Q2 '25



### Highlights:

- Q2 2025 Revenue: \$2.88 million, +100% vs \$1.44 million for Q2 2024
- Q2 2025 Gross Profit: \$1.26 million & profit margin of 43.6% compared to 20.3% in Q2 2024
- As of August 12, 2025, 8,067,580 shares outstanding.
- After quarter end, the Company received \$1 million in non-dilutive funding from STADA and secured \$1.05 million in gross proceeds from additional financings.
- Reiterates revenue guidance of \$13 million for 2025 and expects to achieve positive EBITDA during the year

# Contact Us

## Investor Relations:

KCSA Strategic Communications

Valter Pinto, Managing Director

PH: (212) 896-1254

[NEXGEL@KCSA.com](mailto:NEXGEL@KCSA.com)



NASDAQ: NXGL